Manufacturers: GSK
IDRx-42 is an investigational therapy developed by GSK for the treatment of gastrointestinal stromal tumors (GIST). Positive data were presented at the ASCO oncology conference. The grade 3 adverse event rate is notably lower than competing combination approaches. GSK is working to accelerate the phase III first-line programme for IDRx-42.
IDRx-42 is an investigational therapy developed by GSK for the treatment of gastrointestinal stromal tumors (GIST). Positive data were presented at the ASCO oncology conference. The grade 3 adverse event rate is notably lower than competing combination approaches. GSK is working to accelerate the phase III first-line programme for IDRx-42.
Gastrointestinal stromal tumors (GIST) — first-line treatment (Phase III)
1 associated conditions
